PBLS NASDAQ
Parabilis Medicines, Inc.
1W: +16.5%
1M: +20.7%
YTD: +59.1%
$31.96
+0.14 (+0.44%)
Weekly Expected Move ±11.1%
$24
$28
$31
$35
$38
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$6.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$104.7M
52W Range24.51-34.47
Volume360,840
Avg Volume909,812
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMathai Mammen
Employees145
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-10
Websiteparabilismed.com
30 Acorn Park Dr
Cambridge, MA 02140
US
Cambridge, MA 02140
US
About Parabilis Medicines, Inc.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Latest News
Parabilis Medicines, Inc.’s Quiet Period Will End Tomorrow (NASDAQ:PBLS)
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
SpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History.
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | P-Purchase | 47,250 | $29.77 | 2026-07-22 |
| RA CAPITAL MANAGEMEN | P-Purchase | 21,696 | $27.96 | 2026-07-21 |
| RA CAPITAL MANAGEMEN | P-Purchase | 6,504 | $29.17 | 2026-07-21 |
| RA CAPITAL MANAGEMEN | P-Purchase | 37,723 | $30.00 | 2026-07-21 |
| RA CAPITAL MANAGEMEN | P-Purchase | 98,433 | $27.13 | 2026-07-20 |